期刊文献+

组织中IL-26表达水平对原发性肝细胞癌肝切除患者预后的预测价值

Predictive value of IL-26 expression level in the tissues for the prognosis of hepatocellular carcinoma patients after hepatectomy
下载PDF
导出
摘要 目的探讨组织中白细胞介素-26(IL-26)表达水平对原发性肝细胞癌(HCC)肝切除患者预后的预测价值。方法回顾性分析2011年1月—2014年12月中南大学湘雅医学院附属海口医院行肝切除术的120例HCC患者的临床资料。采用免疫组织化学染色(IHC)方法检测患者癌组织中IL-26的表达,根据IL-26表达水平将患者分为IL-26低表达组(n=62)和IL-26高表达组(n=58)。分析IL-26表达水平与HCC患者临床病理特征及预后的关系;采用Cox比例风险模型对HCC患者术后预后的影响因素进行单因素、多因素分析。结果HCC患者组织中IL-26表达水平与肿瘤直径>5 cm、微血管侵犯、TNMⅢ-Ⅳ期有关(χ^(2)=11.100,P=0.001;χ^(2)=11.257,P=0.001;χ^(2)=6.541,P=0.011)。单因素Cox回归分析结果显示,IL-26高表达、AFP>50μg·L^(-1)、肿瘤直径>5 cm、大血管侵犯、微血管侵犯与HCC患者无复发生存时间(RFS)和总体生存时间(OS)有关(P<0.05);多因素Cox回归分析结果显示,IL-26高表达、肿瘤直径>5 cm、微血管侵犯是HCC患者RFS的独立危险因素(P<0.05),IL-26高表达、微血管侵犯是HCC患者OS的独立危险因素(P<0.05)。Kaplan-Meier法生存曲线显示,IL-26低表达组患者5年RFS和OS高于IL-26高表达组,差异均有统计学意义(χ^(2)=11.002,P=0.001;χ^(2)=8.832,P=0.007)。结论组织中IL-26高表达的HCC术后患者预后较差,IL-26或许可作为HCC患者一种新的预后指标和抗血管治疗靶点。 Objective To investigate the prognostic value of the interleukin-26(IL-26)expression in tissues of hepato-cellular carcinoma(HCC)patients after hepatectomy.Methods The clinical data were analyzed retrospectively of 120 HCC patients who were admitted to the Haikou Affiliated Hospital of Xiangya School of Medicine,Central South University be-tween Jan 2011 and Dec 2014.The expression of IL-26 was detected by immunohistochemical staining.According to the expression levels of IL-26,the patients were divided into IL-26 low expression group(n=62)and IL-26 high expression group(n=58).The relationship between the expression level of IL-26 and the clinicopathological characteristics and prog-nosis was analyzed.Cox proportional risk model was used to analyze the prognostic factors of HCC patients.Results The ex-pression of IL-26 in HCC was correlated with the tumor diameter>5 cm,microvascular invasion and TNM stageⅢ-Ⅳ(χ^(2)=11.100,P=0.001;χ^(2)=11.257,P=0.001;χ^(2)=6.541,P=0.011).Univariate Cox regression analysis showed that high expres-sion of IL-26,AFP>50 ug/L,tumor diameter>5 cm,macrovascular invasion and microvascular invasion were associated with the recurrence-free survival(RFS)and overall survival(OS)of HCC patients.Multivariate Cox regression analysis showed that high expression of IL-26,tumor diameter>5 cm and microvascular invasion were independent risk factors of RFS in HCC patients(P<0.05),and that high expression of IL-26 and microvascular invasion were independent risk factors of OS in HCC patients(P<0.05).Kaplan-Meier survival curve showed that the 5-year RFS and OS of patients with low IL-26 expression were higher than those of patients with high IL-26 expression(χ^(2)=11.002,P=0.001;χ^(2)=8.832,P=0.007).Conclusion The prognosis was poor in HCC patients with high expression of IL-26.The expression level of IL-26 in tissues may be a new prognostic indicator and a target for vascular therapy in HCC patients.
作者 程秋华 符国珍 CHENG Qiuhua;FU Guozhen(Hepatobiliary Surgery Department,Haikou Affiliated Hospital of Xiangya School of Medicine,Central South University,Haikou,570208,Hainan,China)
出处 《肿瘤药学》 CAS 2023年第5期604-609,共6页 Anti-Tumor Pharmacy
关键词 肝细胞癌 白细胞介素-26 无复发生存时间 总体生存时间 Hepatocellular carcinoma Interleukin-26 Recurrence-free survival Overall survival
  • 相关文献

参考文献7

二级参考文献22

  • 1Knappe A, HOr S, Wittmann S, et al. Induction of a novel cellular homolog of interleukin 10, AK155, by transformation of T lymphocytes with herpesvirus saimiri[J]. J Virol, 2000,74 (8):3881-3887.
  • 2Conti P, Kempuraj D, Frydas S, et al. II:10 subfamily members: II:19, II:20, IL-22, IL-24 and II:26 [J]. Immunol Lett,2003,88(3) : 171-174.
  • 3Fickenscher H, Pirzer H. lnterleukin-26[J]. Int lmmuno- pharmacol, 2004,4 ( 5 ) : 609-613.
  • 4Sheikh F, Baurin VV, Lewis Antes A, et al. Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-I 0 receptor 2[j]. J Immunol, 2004,172 (4) : 2006-2010.
  • 5Boniface K, Lecron JC, Bernard FX, et al. Keratinocytes as targets for interleukin-10-related cytokines: a putative role in the pathogenesis o{ psoriasis[J]. Eur Cytokine Netw, 2005,16 (4):309-319.
  • 6Fitzpatrick LR. Novel Pharmacological Approaches for Inflam- matory Bowel Disease: Targeting Key Intracellular Pathways and the II:23/II:17 Axis [J ]. Int J lnflam, 2012, 2012: 389404.
  • 7Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty [J] Immunity, 2012,36 (4) : 503-514.
  • 8Yu H, Pardoll D,Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3 [J]. Nat Rev Cancer, 2009,9( 11 ) : 798-809.
  • 9吴文杰,阳乔,曹芹芳,张耀文,夏雨佳,胡晓文,唐望先.脂筏介导的内源性大麻素对HepG2细胞的作用及其机制[J].中华肝脏病杂志,2010,18(3):204-208. 被引量:3
  • 10徐威,李敬东,赵国刚,田云鸿.改良BCLC分期预测原发性肝细胞癌行根治性肝切除术后早期肝内复发[J].中华肝胆外科杂志,2012,18(1):40-45. 被引量:4

共引文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部